Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3906 in Active Psoriatic Arthritis
NCT07406035Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQH3906 in psoriatic arthritis (PsA), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jul 2026; status: recruiting.
02
Drugs
TQH3906
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07406035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406035.